The Prevalence of Gingival Pigmentation Among a Sample of Adult Egyptian Population.

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05453890
Collaborator
(none)
374
8.4

Study Details

Study Description

Brief Summary

This observational cross-sectional study aims at determining the prevalence of gingival pigmentation among a sample of adult Egyptian patients attending the diagnostic centre at Faculty of Dentistry, Cairo University and identifying its association with other risk factors.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    • Dental patients will be recruited in a consecutive manner from the diagnostic center, Faculty of Dentistry, Cairo University.

    • Medical history will be taken and patients with certain diseases as Addison's disease, Albright's syndrome, Hereditary hemorrhagic telangiectasia, and HIV-associated melanosis or under certain drugs as ACTH, Antimalarial drugs, and Chemotherapeutic agent-busulfan that induce gingival pigmentation will be excluded from the study.

    • Patients who met the inclusion criteria will be subjected to thorough oral examination and a full questionnaire will be filled for each patient. Before filling the questionnaire, the aim of the study will be explained to the patient and the patient's acceptance to participate in the survey will be received.

    • During examining patients, any patient found with suspicious gingival pigmentation, whether the degree of pigmentation, texture, size, or any clinical signs of malignancy, will be referred to the Oral Medicine department for a thorough oral and lymph nodes examination, and biopsy taking if needed. Also, any other suspicious oral lesion noticed will be treated the same way, and a close follow-up for the patient will be done to ensure that the he/she has gone through all possible examination protocols to exclude any possibility of malignancy or abnormal condition that needs intervention.

    • During oral examination of included patients, those will be found to have gingival pigmentation will be classified according to the gingival pigmentation index.

    • Non-respondent patients or patients refusing to participate will be reported with the cause of their refusal.

    • The Questionnaire will be filled through a face-to-face personal interview with the patient using simple, short, easily comprehended questions.

    • The Questionnaire will include a section for information about age, gender, occupation, place of birth and current residential area.

    • Detailed information about smoking type (cigarette, shisha, Vape, IQOS, or others), Smoking Frequency, Smoking duration (no. of years) will be gathered

    • The degree of satisfaction or dissatisfaction with gingival pigmentation, and the willingness to do a surgical or laser procedure to change it will be evaluated by VAS score.

    • Conventional oral examination will be held on a dental unit using the light of the unit.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    374 participants
    Observational Model:
    Ecologic or Community
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Prevalence of Gingival Pigmentation Among a Sample of Adult Egyptian Population: A Cross Sectional Study.
    Anticipated Study Start Date :
    Oct 1, 2022
    Anticipated Primary Completion Date :
    Jan 15, 2023
    Anticipated Study Completion Date :
    Jun 15, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    A sample of adult egyptian population

    Outcome Measures

    Primary Outcome Measures

    1. Prevalence of gingival pigmentation [Up to 30 weeks]

      Gingival Pigmentation Index which classified pigmentation into 4 scores according to the position and extent of the gingival pigments: Score 0: Absence of pigmentation Score 1: Spots of brown to black color or pigments. Score 2: Brown to black patches but not diffuse pigmentation Score 3: Diffuse brown to black pigmentation, marginal, and attached

    Secondary Outcome Measures

    1. Age of the participant associated risk factors [Up to 30 weeks]

      Age in years

    2. Gender of the participant [Up to 30 weeks]

      Male or female

    3. Occupation of the participant [Up to 30 weeks]

      Certain occupations may be a possible risk factor

    4. Type of smoking [Up to 30 weeks]

      Cigarette, shisha, Vape, IQOS,… etc. certain types may be of variable risk factor

    5. Frequency of smoking [Up to 30 weeks]

      Number of Cigarettes/day, In case of other types: daily, weekly, twice weekly, monthly

    6. Duration of smoking [Up to 30 weeks]

      In years

    7. Place of birth [Up to 30 weeks]

      City of birth

    8. Current area of residence [Up to 30 weeks]

      City of residence

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Adult patients whose age is 18 years old and above.

    • Patient consulting in the diagnostic centre, Faculty of Dentistry, Cairo University.

    • Provide informed consent.

    Exclusion Criteria:
    • Systemic diseases and syndromes known to be associated with oral melanin pigmentation, such as Addison's disease, Albright's syndrome, Hereditary hemorrhagic telangiectasia, and HIV-associated melanosis (Peeran et al 2014).

    • Patients taking certain drugs that predispose to drug-induced melanin pigmentation, such as: ACTH, Antimalarial drugs, and Chemotherapeutic agent-busulfan (Peeran et al 2014).

    • Tattoos of the oral mucosa

    • Patients having problem in opening their mouth or undergoing inter-maxillary fixation where oral examination will not be possible.

    • Patients diagnosed with psychiatric problems.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Cairo University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Peter Onsi Doss Hanna, Principal investigator, Cairo University
    ClinicalTrials.gov Identifier:
    NCT05453890
    Other Study ID Numbers:
    • POD 1
    First Posted:
    Jul 12, 2022
    Last Update Posted:
    Jul 12, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jul 12, 2022